PATENT CLAIM ANALYSIS

Application Number: 16087252
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["544", "058200"]

Abstract:
The present disclosure disclosed crystalline forms of Filgotinib hydrochloride for treating or preventing JAK-associated diseases, and preparation methods, pharmaceutical compositions, and formulations thereof. The present disclosure also disclosed the use of crystalline forms of Filgotinib hydrochloride in the prevention and/or treatment of diseases associated with JAK family. In comparison to the known crystalline forms, the crystalline forms of the present disclosure show more favorable properties in terms of formulation engineering, such as higher stability under low water activity conditions, simplicity in the preparation process and/or higher solubility.

Claim (Index 20):
A preparation method of crystalline Form D according to  claim 17 , wherein the method comprises:\n Adding Filgotinib free base in alcohols, adding hydrochloric acid, stirring at certain temperature to crystallize, then separating and drying to obtain Form D; Or alternatively adding known crystalline form of Filgotinib.HCl.3H 2 O in alcohol, stirring at certain temperature to crystallize, then separating and drying to obtain Form D.

Metadata:
- Claim Count in Document: 48.0
- Percentile: 97.0
- Lexical Diversity: 1.65517
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16322610', '16079764', '16304280', '16065350', '15579881']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8284479540788818
- 35 USC 102 Novelty (BERT): 0.5424941442305224
- Combined Prediction Score: 0.7998525730940459
- Mean Citation Score: 392.497
- Max Citation Score: 412.81427
- Similarity Product: 295.9554537068582

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test